





Supplemental Figures for:
Anlotinib monotherapy for refractory metastatic colorectal cancer: A double-blinded, placebo controlled, randomized Phase III trial (ALTER0703)
Jianqiang Cai et al.


Supplementary Figure 1. Subgroup analysis of overall survival for patients with or without subsequent systemic anti-tumor therapy. (A) Overall survival of patients who did not receive subsequent systemic anti-tumor therapy in anlotinib group and placebo group was 6.87 months (95% CI 6.14-7.69) and 4.47 months (3.29-6.14), respectively, with a HR of 0.66 (95% CI 0.49-0.89). (B) Overall survival of patients who received subsequent systemic anti-tumor therapy was 13.14 months (10.74-15.31) in anlotinib group and 13.63 months (8.71-17.81) in placebo group, with a HR of 1.09 (0.78-1.54)




Supplementary Figure 2. Subgroup analysis of overall survival for patients with or without subsequent chemotherapy. (A) Overall survival of patients who did not receive subsequent chemotherapy was 7.16 months (95% CI 6.41-8.05) in anlotinib group and 5.68 months (4.21-6.60) in placebo group, with a HR of 0.73 (95% CI 0.56-0.95). (B) Overall survival of patients who received subsequent chemotherapy was 13.36 months (10.68-16.53) in anlotinib group and 17.41 months (13.14-23.85) in placebo group, with a HR of 1.31 (0.88-1.97)



Supplementary Figure 3. Water-fall plots for treatment response of anlotinib (A) and Placebo (B)



Supplementary Figure 4. mean changes of QLQ C-30 scores at the end of 2nd (A) , 4th (B) and 6th (C) treatment cycle from baseline



Supplementary Figure 5. mean changes of EQ-5D scores at the end of 2nd (A) , 4th (B) and 6th (C) treatment cycle from baseline

